FDA approves zolbetuximab-clzb with chemotherapy for gastric or gastroesophageal junction adenocarcinoma

Trials

Spotlight, GLOW

Drug

Vyloy (zolbetuximab-clzb) · Anti-CLDN18.2 antibody

Condition

Gastrointestinal